ApoB: The Superior Marker for Guiding Cholesterol Treatment That Saves Lives and Money

New research shows that using apolipoprotein B (ApoB) to guide cholesterol-lowering therapy is not only more effective but also cost-effective compared to current standard approaches

🎧 ▶️ Press the play button below to listen.

Introduction

For decades, doctors have relied on low-density lipoprotein cholesterol (LDL-C) – the so-called “bad cholesterol” – as the primary target for cholesterol-lowering therapy. However, a groundbreaking study published in the Journal of the American Medical Association (JAMA) in April 2026 challenges this long-standing practice.

The research, conducted by a team from the Northwestern University Feinberg School of Medicine and other leading institutions, demonstrates that using apolipoprotein B (ApoB) to guide treatment decisions is not only more effective at preventing heart attacks and strokes but also a cost-effective strategy for the American healthcare system.

This article breaks down the study’s findings, explaining why ApoB matters, how the research was conducted, and what these results mean for patients and healthcare providers.

---

Understanding the Basics: What Are We Measuring?

Before diving into the study, it’s helpful to understand what these different markers represent.

LDL-C: The Traditional Target

LDL-C measures the amount of cholesterol carried by low-density lipoproteins. Think of it as measuring the total weight of cargo being transported by delivery trucks. While this has been the standard measure for decades, it doesn’t tell the complete story.

Non-HDL-C: A Broader Measure

Non-HDL-C includes all the “bad” cholesterol particles – not just LDL but also very-low-density lipoprotein (VLDL) and others. This provides a more comprehensive picture than LDL-C alone.

ApoB: Counting the Trucks, Not Just the Cargo

Apolipoprotein B (ApoB) is different. Instead of measuring how much cholesterol is being carried, ApoB counts the actual number of atherogenic particles – the delivery trucks themselves. Each particle that can cause atherosclerosis contains exactly one ApoB molecule, making it a direct measure of particle number.

This distinction matters because:

• Particles can contain varying amounts of cholesterol
• Two people with the same LDL-C level can have very different numbers of particles
• The number of particles, not just their cholesterol content, drives cardiovascular risk

---

Why ApoB May Be Superior

The study’s authors note that ApoB is a “superior marker of residual atherosclerotic cardiovascular disease risk” in patients already taking lipid-lowering therapy. If you’re already on statins or other cholesterol medications, knowing your ApoB level gives your doctor a better idea of your remaining risk than LDL-C or non-HDL-C.

This makes biological sense. Atherosclerosis – the buildup of plaque in arteries – occurs when these particles enter the artery wall and trigger inflammation. Every ApoB-containing particle has the potential to do this, regardless of how much cholesterol it happens to be carrying.

The research team also points out that statins reduce cholesterol mass more efficiently than they reduce particle number. This means that if you’re only tracking LDL-C, you might think treatment is working well when, in fact, dangerous particles remain.

---

The Study Design: A Brief Overview

The researchers used a sophisticated computer simulation model, the Cardiovascular Disease Policy Model, to evaluate the cost-effectiveness of three treatment strategies.

The Simulation Cohort

The team constructed a cohort of 250,000 statin-eligible adults without existing cardiovascular disease. These individuals were statistically representative of the U.S. population, drawn from National Health and Nutrition Examination Survey (NHANES) data from 2005 to 2016.

The Three Strategies

1. LDL-C goal (current standard of care): Intensify treatment if LDL-C remains above 100 mg/dL
2. Non-HDL-C goal: Intensify treatment if non-HDL-C remains above 118 mg/dL
3. ApoB goal: Intensify treatment if ApoB remains above 78.7 mg/dL

The non-HDL-C and ApoB targets were chosen as percentile equivalents to the LDL-C target, meaning they correspond to the same position in the population distribution.

Treatment Intensification

When patients didn’t meet their target, treatment was intensified in steps:

1. Moderate-intensity statins → High-intensity statins
2. High-intensity statins → High-intensity statins plus ezetimibe

The model tracked lifetime costs, quality-adjusted life years (QALYs), and cardiovascular events.

Understanding QALYs: The Metric That Measures Both Quantity and Quality of Life

To fully appreciate why the ApoB strategy is considered cost-effective, it helps to understand the primary metric the researchers used: the Quality-Adjusted Life Year, or QALY (pronounced “kwah-lee”).

What Exactly Is a QALY?

A QALY is a measure that combines two essential aspects of health into a single number:

1. Length of life (how many years you live)
2. Quality of life (how healthy and functional those years are)

Think of it this way: If perfect health is worth 1.0 per year, and death is worth 0, then:

• One year in perfect health = 1.0 QALY
• One year in less-than-perfect health = less than 1.0 QALY (e.g., 0.8 for mild limitations, 0.5 for significant disability)
• One year in a health state considered worse than death = less than 0 QALY

A Practical Example

Imagine two people, both living for 10 years:

Person	Health State	Years	QALYs Earned
Person A	Perfect health (1.0)	10	10.0 QALYs
Person B	Moderate disability (0.6)	10	6.0 QALYs

Even though both lived 10 years, Person A earned 10 QALYs while Person B earned only 6 QALYs. The difference reflects the lower quality of life experienced by Person B.

How QALYs Are Calculated in This Study

The researchers assigned utility values (quality weights) to different health states based on published literature:

• Perfect health = 1.0
• After a non-fatal heart attack = reduced quality of life for a period
• After a stroke = potentially significant reduction in quality of life, depending on severity
• On statin therapy = a small disutility (pill-taking burden, minor side effects)
• With statin-induced diabetes = a modest reduction in quality of life

Why QALYs Matter for Cost-Effectiveness

QALYs allow researchers to compare very different health interventions on a common scale. For example:

• A cancer treatment might extend life by 2 years but with significant side effects (maybe 0.7 QALYs per year = 1.4 QALYs gained)
• A cholesterol treatment might extend life by 3 years with minimal side effects (0.95 QALYs per year = 2.85 QALYs gained)

Even though the cancer treatment extends life for 2 years and the cholesterol treatment for 3, the QALY calculation tells us which provides more meaningful health benefit.

The Cost-Effectiveness Threshold

In the United States, interventions are generally considered cost-effective if they cost less than $100,000 to $150,000 per QALY gained. The AHA/ACC recommends a threshold of $120,000 per QALY, which is what this study used.

So when the researchers found that the ApoB strategy costs **$30,300 per QALY gained**, they were saying: “For every additional year of perfect-quality life we give people by using ApoB guidance, we spend about $30,000.” Since this is well below the $120,000 threshold, the strategy represents good value for money.

The 1,324 QALYs Gained: What Does That Mean?

In the study, the ApoB strategy produced 1,324 additional QALYs compared to the non-HDL-C strategy for a cohort of 250,000 people. This means:

• Across the entire population studied, people collectively experienced the equivalent of 1,324 extra years of perfect health
• This could manifest as:
  • 1,324 people living one extra year in perfect health
  • 2,648 people living an extra six months in perfect health
  • Or some combination of extended life and improved quality of life

QALYs vs. Life-Years

The study also reported life-years gained – a simpler measure that counts only length of life, not quality. For the ApoB strategy:

• Life-years gained: 3,193 additional life-years
• QALYs gained: 1,324 additional QALYs

The difference (3,193 vs. 1,324) reflects that some of those extra years are lived with reduced quality of life – perhaps due to aging, non-cardiovascular conditions, or the minor burdens of ongoing treatment.

Why This Matters for Your Health

When your doctor recommends a treatment, they’re thinking about both how long you’ll live and how well you’ll live. The QALY framework captures both dimensions.

The ApoB strategy isn’t just about preventing heart attacks – it’s about preventing disabling events like strokes that can dramatically reduce quality of life, while also extending life expectancy.

A Note on Discounting

The researchers applied a 3% annual discount rate to both costs and QALYs. This is standard practice in health economics and reflects the concept that:

• A year of healthy life today is worth more than a year of healthy life in the future
• A dollar spent today is worth more than a dollar spent in the future

This discounting makes the analysis more conservative and reflects real-world economic and health preferences.

---

In summary: QALYs provide a way to measure the true value of health interventions by considering both how long people live and how well they live. The finding that ApoB guidance costs approximately $30,300 per QALY gained represents excellent value by U.S. standards, supporting the case for adopting this approach in clinical practice.

With this understanding of how the researchers measured health benefits, we can now turn to the study’s most important question: What did they actually find? 

The results, detailed below, reveal a clear pattern favoring ApoB-guided therapy across multiple measures of effectiveness and cost.

---

The Key Findings: What the Research Revealed

ApoB Guidance Saves More Lives

The results were striking:

• Compared to the LDL-C approach, using a non-HDL-C goal would produce 965 additional QALYs (quality-adjusted life years) per 250,000 patients
• Compared to non-HDL-C, using an ApoB goal would produce 1,324 additional QALYs
• ApoB guidance would prevent approximately 1,018 additional cardiovascular events compared to non-HDL-C

The Cost Picture: Surprisingly Favorable

Despite being more effective, the ApoB strategy proved cost-effective:

• The non-HDL-C strategy was actually cost-saving compared to LDL-C guidance (saving about $2.1 million)
• The ApoB strategy cost $30,300 per QALY gained compared to non-HDL-C
• This is well below the standard cost-effectiveness threshold of $120,000 per QALY

What About the Cost of ApoB Testing?

One common concern about switching to ApoB is the additional cost of the test. The study found that:

“The cost of ApoB testing was marginal; higher costs reflected longer life expectancy and prolonged preventive treatment.”

In other words, the increased costs came from patients living longer and therefore receiving treatment for more years – not from the testing itself. This is a feature, not a bug, as it indicates the treatment is successfully extending lives.

Probabilistic Analysis: ApoB Wins Most of the Time

The researchers conducted 1,000 probabilistic simulations to account for uncertainty. The results were compelling:

• ApoB goal was optimal in 65% of simulations
• Non-HDL-C goal was optimal in 25%
• LDL-C goal was optimal in only 10%

This means that even when accounting for statistical uncertainty, ApoB guidance is highly likely to be the best approach.

---

How ApoB Leads to Better Outcomes

The study’s findings become intuitive when you understand the underlying biology:

1. Better risk identification: ApoB more accurately identifies patients who remain at risk despite treatment
2. More targeted intensification: Treatment is intensified for those who need it most
3. Greater event reduction: More appropriate targeting leads to fewer heart attacks and strokes
4. Longer lives: Preventing cardiovascular events extends life expectancy
5. More treatment years: Longer life means more years on preventive therapy

This chain of benefits explains why the ApoB strategy increases both health outcomes and costs – but does so in a cost-effective manner.

---

Sex-Specific Findings

The researchers also analyzed men and women separately to ensure the results held true across both sexes. Before diving into the numbers, it’s helpful to understand what ICER means.

What Is ICER?

ICER stands for Incremental Cost-Effectiveness Ratio. It’s the key metric used in cost-effectiveness analysis to compare two treatment strategies. The formula is simple:

ICER = (Cost of Strategy A – Cost of Strategy B) ÷ (QALYs of Strategy A – QALYs of Strategy B)

In plain English, the ICER tells you how much it costs to gain one additional QALY by choosing one strategy over another. For example, if Strategy A costs $50,000 more than Strategy B but produces 1 additional QALY, the ICER is $50,000 per QALY gained.

The lower the ICER, the better the value. In the United States, interventions with an ICER below $120,000 per QALY are generally considered cost-effective, which is the threshold used in this study.

Results for Women and Men

When the researchers analyzed the sexes separately, they found that ApoB guidance was cost-effective for both:

• For women, ApoB guidance had an ICER of $35,900 per QALY compared to non-HDL-C guidance
• For men, ApoB guidance had an ICER of $26,600 per QALY compared to non-HDL-C guidance

Both values are well below the standard cost-effectiveness threshold, indicating that ApoB guidance is cost-effective for both sexes. Interestingly, the approach was slightly more cost-effective for men than for women, though the difference was relatively modest.

---

Sensitivity Analyses: Testing the Robustness

The researchers conducted extensive “what-if” analyses to test whether their conclusions held up under different assumptions. Key findings:

• “Intensify all” would be most effective but least clinically acceptable
• Even when forcing the same number of people to be treated in each strategy, ApoB consistently produced the most health benefits
• The results remained valid across a wide range of plausible modeling assumptions

The most influential factors were:

1. The relationship between ApoB reduction and stroke risk
2. The effectiveness of various lipid-lowering therapies at reducing ApoB

---

Implications for Clinical Practice

What This Means for Patients

If you’re currently taking or considering cholesterol-lowering therapy:

• Your doctor may eventually start using ApoB rather than LDL-C to guide your treatment
• This could lead to more personalized therapy and better outcomes
• The additional testing cost appears to be minimal relative to the benefits

What This Means for Healthcare Systems

• Population health would likely improve with ApoB-guided therapy
• Cost-effectiveness is favorable despite potentially higher upfront costs
• The approach aligns with the broader trend toward precision medicine

A Note on Out-of-Pocket Costs for Patients

It’s important to acknowledge that this study was conducted from a health sector perspective, meaning it evaluated costs from the viewpoint of the healthcare system – insurers, Medicare, and other payers. The analysis assumed that the cost of ApoB testing would be borne by the healthcare system, not directly by patients.

But what if you’re a patient paying for these tests out of your own pocket? Here’s what you should know:

The Cost of ApoB Testing

In the United States, the out-of-pocket cost for an ApoB test typically ranges from $50 to $150 when ordered directly by a patient, though prices vary widely depending on the laboratory and geographic location. By comparison, a standard lipid panel (which measures LDL-C, HDL-C, and triglycerides) generally costs $20 to $50 out of pocket.

Is It Worth It for the Self-Paying Patient?

While this study didn’t directly analyze the cost-effectiveness from the patient’s perspective, the findings suggest that for most patients, the additional benefit of ApoB guidance likely outweighs the modest extra cost of the test. Consider:

• Better risk assessment: ApoB more accurately identifies whether you’re truly at risk, potentially avoiding unnecessary treatment intensification for some patients
• More effective treatment: If treatment is intensified based on ApoB, you’re more likely to receive the right therapy
• Preventing costly events: Avoiding just one heart attack or stroke can save tens or hundreds of thousands of dollars in medical costs – far more than the cost of a few extra tests

A Few Practical Considerations

• Check with your insurance: Many insurance plans do cover ApoB testing, especially if your doctor documents that it’s medically necessary. It’s worth calling your insurer to ask.
• Medicare coverage: Medicare typically covers lipid panel testing but coverage for ApoB specifically can vary. Some Medicare Advantage plans may cover it, while traditional Medicare may not in all circumstances.
• Shop around: If you’re paying cash, prices for laboratory tests can vary dramatically. Websites like Walk-In Lab or local independent laboratories often offer lower prices than hospital-based labs.
• Discuss with your doctor: Ask your physician whether ApoB testing would meaningfully change your treatment plan. If the answer is yes, the out-of-pocket cost may be a worthwhile investment in your health.
• Consider the bigger picture: Even if you pay $100 for an ApoB test, the potential benefit – better-informed treatment decisions, potentially fewer medications, and lower long-term cardiovascular risk – represents excellent value for many patients.

A Word of Caution

It’s also worth noting that the study evaluated population-level cost-effectiveness. For any individual patient, the value of ApoB testing depends on your specific risk profile, your current treatment status, and how your doctor would use the results. ApoB testing is most valuable when it leads to a change in management – either intensifying treatment for those at higher risk or potentially avoiding unnecessary intensification for those at lower risk.

Bottom line for self-paying patients: If your doctor recommends ApoB testing and you’re paying out of pocket, the evidence suggests it’s likely a worthwhile investment in your long-term health, provided the test results would actually change your treatment plan. However, always discuss the potential benefits and costs with your healthcare provider before proceeding.

---

Addressing Potential Concerns

“Aren’t LDL-C tests cheaper?”

While LDL-C tests are indeed less expensive, the study found that the testing cost itself plays a “minimal role” in the overall cost-effectiveness equation. The bigger cost drivers are treatment-related.

“Isn’t this just over-treating more people?”

The researchers specifically tested this by designing strategies that treated the same number of people. Even when controlling for the number of patients receiving intensified treatment, ApoB guidance produced better outcomes.

“What about clinical guidelines?”

The 2018 American Heart Association/American College of Cardiology guidelines currently focus on LDL-C and non-HDL-C. However, European guidelines already recommend ApoB as an alternative target. This study provides strong evidence for reconsidering U.S. guidelines.

---

Limitations Worth Noting

No study is perfect, and the authors acknowledge several limitations:

1. Simulation-based evidence: This is a computer model, not a clinical trial. While well-validated, it still involves assumptions.
2. Imputed ApoB values: ApoB wasn’t measured in all the underlying studies used to build the model, so some values were estimated.
3. Health sector perspective: The analysis didn’t include broader societal benefits like reduced workplace absenteeism.
4. Uncertainty intervals: Some estimates crossed zero, indicating statistical uncertainty, although probabilistic analyses strongly favored ApoB.

---

The Bottom Line: What This Research Tells Us

This JAMA study provides compelling evidence that measuring and targeting ApoB could improve cardiovascular outcomes while remaining cost-effective.

The superiority of ApoB makes biological sense – it directly counts the number of dangerous particles rather than indirectly estimating their cholesterol content. This allows for more precise risk assessment and more targeted treatment intensification.

---

More ApoB Articles

We encourage readers interested in this topic to explore our other articles on ApoB and cholesterol management:

1. How to Interpret ApoB and ApoA1 Results
2. ApoB Reveals Hidden Heart Disease And Diabetes Risk Early
3. The Truth About Cholesterol And Fasting Lies In ApoB
4. ApoB vs LDL Cholesterol: Which Predicts Heart Attacks Better
5. ApoB and ApoA1 Best Predict Heart Attack: How To Get Tested
6. When Exercise Lowers ApoB but Not LDL: What It Means for Overweight Adults
7. Near-Infrared Light Proven to Improve Key Lab Markers

---

Key Takeaways

What the research found:

• ApoB-guided therapy is more effective at preventing cardiovascular events than current LDL-C-based approaches
• ApoB guidance is cost-effective, costing approximately $30,300 per quality-adjusted life year gained
• ApoB was the optimal strategy in 65% of probabilistic simulations versus only 10% for LDL-C

Why it matters:

• ApoB more accurately identifies patients who remain at risk despite treatment
• Better targeting leads to fewer heart attacks and strokes
• Lives saved mean longer treatment duration, which explains higher costs but also demonstrates benefit

What it means for you:

• If you’re on cholesterol-lowering therapy, ask your doctor about ApoB testing
• The shift from LDL-C to ApoB represents an evolution toward more precise medicine
• This research supports a potential change in clinical guidelines

The big picture:

ApoB is emerging as the superior marker for guiding lipid-lowering therapy in primary prevention, and this study demonstrates that adopting it would improve population health while representing good value for healthcare dollars.

---

This article summarizes research published in JAMA (2026; doi:10.1001/jama.2026.2986). For a complete understanding of the study methodology and findings, readers are encouraged to review the original publication.

Don’t Get Sick!

About Dr. Jesse Santiano, MD

Dr. Santiano is a retired internist and emergency physician with extensive clinical experience in metabolic health, cardiovascular prevention, and lifestyle medicine. He reviews all medical content on this site to ensure accuracy, clarity, and safe application for readers. This article is for educational purposes and is not a substitute for personal medical care.

💡 Support This Work

Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.

🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!

Follow me on Facebook, Gab, Twitter (formerly known as X), Instagram, and Telegram.

Articles on Biomarkers and Atherosclerosis

1. Your Lipid Tests Recap: What They Mean, How To Improve
2. Understanding Your Ferritin: What It Means and How to Improve It
3. Understanding Chronic Inflammation And Simple Ways To Reverse It
4. How High Fibrinogen Signals Hidden Inflammation And Cardiovascular Risk
5. Understanding Homocysteine And Simple Ways To Lower It Naturally
6. Understanding FBS, HbA1c, and eAG at a Glance
7. Using MPO Testing To Better Understand Cardiovascular Disease Risk
8. How Lp-PLA2 Helps Predict Strokes Before They Actually Happen
9. Simple Ways To Lower Remnant Cholesterol And Protect Your Heart
10. Lower Your Non-HDL Cholesterol Naturally For Better Long-Term Health
11. Understanding Your CRP vs Lp(a) To Improve Your Heart Health
12. Is Your GGT Too High? Early Warning Signs and How to Lower It
13. Understanding Your Ferritin: What It Means and How to Improve It
14. The TyG Index: A Powerful Predictor Of Insulin Resistance, Heart Disease Risk And More
15. Knowing Your hs-CRP: What It Means and How to Improve It
16. Understanding Your ApoB: What It Means and How to Improve It
17. Understanding Your Lipoprotein(a): What It Means and How to Improve It

References:

1. Luebbe S, Sniderman AD, Moran AE, Wilkins JT, Kohli-Lynch CN. Cost-Effectiveness of ApoB, Non–HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy. JAMA. 2026;335(17):1507–1514. doi:10.1001/jama.2026.2986 https://jamanetwork.com/journals/jama/article-abstract/2847303
2. Kazi DS, Elkind MSV, Deutsch A, et al; American Heart Association. Forecasting the economic burden of cardiovascular disease and stroke in the United States through 2050: a presidential advisory from the American Heart Association. Circulation. 2024;150(4):e89-e101. doi:10.1161/CIR.0000000000001258
3. Kohli-Lynch CN, Thanousolis G, Moran AE, Sinderman AD. The clinical utility of apoB versus LDL-C/non-HDL-C. Clin Chim Acta. 2020;508:103-108. doi:10.1016/j.cca.2020.05.001
4. Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625
5. Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. 2019 ESC/EA guidelines for the management of dyslipidaemia: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455
6. Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the National Lipid Association. J Clin Lipidol. 2024;18(5):e647-e663. doi:10.1016/j.jacl.2024.08.013
7. Ference BA, Kastelien JP, Ray KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364-373. doi:10.1001/jama.2018.20045
8. Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. J Am Coll Cardiol. 2021;77(11):1439-1450. doi:10.1016/j.jacc.2021.01.027
9. Thanousolis G, Williams K, Ye K, et al. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. J Am Heart Assoc. 2014;3(2):e000759. doi:10.1161/JAHA.113.000759
10. Kohli-Lynch CN, Bellows BK, Zhang Y, et al. Cost-effectiveness of lipid-lowering treatments in young adults. J Am Coll Cardiol. 2021;78(20):1954-1964. doi:10.1016/j.jacc.2021.08.065
11. Kohli-Lynch CN, Bellows BK, Thanousolis G, et al. Cost-effectiveness of low-density lipoprotein cholesterol level-guided statin treatment in patients with borderline cardiovascular risk. JAMA Cardiol. 2019;4(10):969-977. doi:10.1001/jamacardio.2019.2851
12. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. Accessed July 10, 2024. https://www.ahajournals.org/doi/10.1161/01.cir.0000437741.48606.98
13. Husereau D, Drummond M, Augustovski F, et al: CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022;20(1):23. doi:10.1186/s12916-021-02204-0
14. Oelsner EC, Balte PP, Cassano PA, et al. Harmonization of respiratory data from 9 US population-based cohorts: the NHLBI Pooled Cohorts Study. Am J Epidemiol. 2018;187(11):2265-2278. doi:10.1093/aje/kwy139
15. NHANES questionnaires, datasets, and related documentation. Centers for Disease Control and Prevention. Accessed October 1, 2025. https://www.cdc.gov/Nchs/Nhanes/
16. Toth PP, Bray S, Villa G, et al. Network meta-analysis of randomized trials evaluating the comparative efficacy of lipid-lowering therapies added to maximally tolerated statins for the reduction of low-density lipoprotein cholesterol. J Am Heart Assoc. 2022;11(18):e025551. doi:10.1161/JAHA.122.025551
17. Descamps O, Tomassini JE, Lin J, et al. Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. Atherosclerosis. 2015;240(2):482-489. doi:10.1016/j.atherosclerosis.2015.03.004
18. Khan SU, Khan MU, Valavoor S, et al. Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: systematic review and meta-analysis of trials. Eur J Prev Cardiol. 2020;27(12):1255-1268. doi:10.1177/2047487319871733
19. Baigent C, Blackwell L, Emberson J, et al; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. doi:10.1016/S0140-6736(10)61350-5

Disclaimer:
This article is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions based on the TyG Index or other biomarkers.

© 2018 – 2026 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment

As an Amazon Associate, I earn from qualifying purchases